Sansheng Pharmaceutical Antibody Drug Product sinia® (recombinant anti-CD25 human-derived monoclonal antibody injection) obtains drug GMP certificate

yesterday (June 25), China's leading bio
pharmaceutical(http://company(http://Sansheng Pharmaceuticals (01530HK) announced that the company's self-developed antibodydrug(http://product(http://Kinegasin ® (common name: recombinant anti-CD25 humanized monoclonal antibody injection) has been awarded the NationalDrug(http://Regulatory Authority of the drug GMP certificateAbout Kenniyi ®
Kenniyi ® is the first approved human-derived monoclonal antibody, used to prevent acute rejection reaction caused by kidney transplantation, can be combined with conventional immunosuppressive programs, significantly improve the survival rate of transplanted organs, improve the quality of life of patients 　　Kidney transplantation is one of the best treatments for patients with end-stage renal disease For the latter of kidney transplants, the degree of immune rejection response seriously affects the transplanted kidney survival time, thus further affecting the quality of life of the recipient Acute rejection reactions occur mostly within the first 3 months of transplantation and are the most common type of rejection 　　According to the China Kidney Transplant Science Registration System (CSRKT) data, a total of 10,387 patients in China underwent kidney transplants in 2017, and with the increase in the number of organ donations showed a clear upward trend, while the current domestic kidney transplant patients have limited access to similar drugs, the listing of the ® will provide domestic patients with more economical options and reduce the burden on patients